Literature DB >> 10064660

Neonatal onset ornithine transcarbamylase deficiency: A retrospective analysis.

N E Maestri1, D Clissold, S W Brusilow.   

Abstract

OBJECTIVE: A retrospective analysis of 74 cases of neonatal-onset ornithine transcarbamylase (OTC) deficiency.
METHODS: The medical records of 74 of the 128 male patients referred to this center with neonatal onset OTC from 1976 to 1996 were available and analyzed.
RESULTS: Initial symptoms of OTC deficiency were nonspecific and included feeding difficulties, lethargy, and "respiratory distress"; vomiting was infrequent. Respiratory alkalosis was regularly observed; the mean pH and pCO2 were 7.5 and 24 torr, respectively. Early consideration of a metabolic disorder in those neonates with a negative family history was only 9%. Sepsis was initially misdiagnosed in 50% of the cases. For all patients the mean age at onset was 63 hours. Survival was better among those who had later onset, later diagnostic studies, and diagnosis. Apart from 1 patient whose peak ammonium level was 400 micromol/L, all surviving patients had severe developmental delay.
CONCLUSIONS: OTC deficiency should be suspected in term infants who have early signs of encephalopathy, particularly after the first 24 hours; a respiratory alkalosis is pathognomic of urea cycle disorders. Severe developmental delay is the usual outcome of OTC deficiency.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10064660     DOI: 10.1016/s0022-3476(99)70448-8

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  32 in total

Review 1.  Ornithine carbamoyltransferase deficiency.

Authors:  J E Wraith
Journal:  Arch Dis Child       Date:  2001-01       Impact factor: 3.791

Review 2.  Detection of inborn errors of metabolism in the newborn.

Authors:  A Chakrapani; M A Cleary; J E Wraith
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2001-05       Impact factor: 5.747

3.  Ornithine transcarbamylase deficiency of a male newborn with fatal outcome.

Authors:  Benno Hartung; Oliver Temme; Eva Neuen-Jacob; Stefanie Ritz-Timme; Katrin Hinderhofer; Thomas Daldrup
Journal:  Int J Legal Med       Date:  2016-01-11       Impact factor: 2.686

4.  Neurological outcome of patients with ornithine carbamoyltransferase deficiency.

Authors:  P Nicolaides; D Liebsch; N Dale; J Leonard; R Surtees
Journal:  Arch Dis Child       Date:  2002-01       Impact factor: 3.791

5.  Ornithine transcarbamylase deficiency with persistent abnormality in cerebral glutamate metabolism in adults.

Authors:  Andrea L Gropman; Napapon Sailasuta; Kent C Harris; Osama Abulseoud; Brian D Ross
Journal:  Radiology       Date:  2009-06-30       Impact factor: 11.105

6.  Urea cycle disorders: brain MRI and neurological outcome.

Authors:  William R Bireley; Johan L K Van Hove; Renata C Gallagher; Laura Z Fenton
Journal:  Pediatr Radiol       Date:  2011-10-12

7.  Phenotypic correction of ornithine transcarbamylase deficiency using low dose helper-dependent adenoviral vectors.

Authors:  Nicola Brunetti-Pierri; Christian Clarke; Viraj Mane; Donna J Palmer; Brendan Lanpher; Qin Sun; William O'Brien; Brendan Lee
Journal:  J Gene Med       Date:  2008-08       Impact factor: 4.565

8.  Female heterozygotes for the hypomorphic R40H mutation can have ornithine transcarbamylase deficiency and present in early adolescence: a case report and review of the literature.

Authors:  Jason R Pinner; Mary-Louise Freckmann; Edwin P Kirk; Makoto Yoshino
Journal:  J Med Case Rep       Date:  2010-11-12

9.  Intellectual, adaptive, and behavioral functioning in children with urea cycle disorders.

Authors:  Lauren Krivitzky; Talin Babikian; Hye-Seung Lee; Nina Hattiangadi Thomas; Karen L Burk-Paull; Mark L Batshaw
Journal:  Pediatr Res       Date:  2009-07       Impact factor: 3.756

10.  Gene therapy for inborn errors of liver metabolism: progress towards clinical applications.

Authors:  Nicola Brunetti-Pierri
Journal:  Ital J Pediatr       Date:  2008-11-18       Impact factor: 2.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.